Clinical case of achieving compensation for type 2 diabetes mellitus in preparation for pregnancy in a woman of reproductive age
- Authors: Markina J.M.1
-
Affiliations:
- D.O. Ott Research Institute of Obstetrics and Gynecology
- Issue: Vol 31, No 2 (2024)
- Pages: 158-160
- Section: Clinical case
- URL: https://journals.eco-vector.com/2073-4034/article/view/632470
- DOI: https://doi.org/10.18565/pharmateca.2024.2.158-160
- ID: 632470
Cite item
Open Access
Access granted
Abstract
A clinical case of a patient with newly diagnosed type 2 diabetes mellitus (DM2) is presented. The patient with a diagnosis of “impaired glucose tolerance” was not seen by an endocrinologist, did not follow a diet, independently discontinued the prescribed metformin, and did not control her glycemic level. She consulted an endocrinologist when started planning her pregnancy. The patient was diagnosed with type 2 diabetes mellitus, and combination glucose-lowering therapy was recommended. Next, the selection of therapy was assessed, the reliable long-term compensation of diabetes was achieved, and the long-awaited pregnancy occurred.
Conclusion. Therapy with gosogliptin has proven its effectiveness and safety in early treatment using rational combinations of drugs with a high safety profile.
Full Text
About the authors
J. M. Markina
D.O. Ott Research Institute of Obstetrics and Gynecology
Author for correspondence.
Email: juliamarkinaendo@gmail.com
Endocrinologist
Russian Federation, St. PetersburgReferences
- Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й выпуск. Сахарный диабет. 2021;24(1S.):1–148. doi: 10.14341/DM12802.
- Sun H., Saeedi P., Karuranga S., et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diab Res Clin Pract. 2022;183(Art. ID):109119. doi: 10.1016/j.diabres.2021.109119.
- Галстян К.О., Недосугова Л.В., Петунина Н.А. и др. Первый отечественный ингибитор ДПП-4 госоглиптин в сравнении с вилдаглиптином при лечении пациентов с сахарным диабетом 2 типа. Сахарный диабет. 2016;19(1):89–96. [Galstyan K.O., Nedosugova L.V., Petunina N.A., Trakhtenberg J.A., Vostokova N.V., Karavaeva O.V., Chasovskaya T.E. First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients. Diabetes mellitus. 2016;19(1):89-96. (In Russ.)]. Doi: 10.14341/ DM7233.
- Knowler W.C., Barret-Connor E., Fowler S.E., et al. Reduction in the Incidence of type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002;346(6):393–403. doi: 10.1056/NEJMoa012512.
Supplementary files
